Receipt of Glucose Testing and Performance of Two US Diabetes Screening Guidelines, 2007-2012

Kai McKeever Bullard, Mohammed K Ali, Giuseppina Imperatore, Linda S Geiss, Sharon H Saydah, Jeanine B Albu, Catherine C Cowie, Nancy Sohler, Ann Albright, Edward W Gregg, Kai McKeever Bullard, Mohammed K Ali, Giuseppina Imperatore, Linda S Geiss, Sharon H Saydah, Jeanine B Albu, Catherine C Cowie, Nancy Sohler, Ann Albright, Edward W Gregg

Abstract

Background: Screening guidelines are used to help identify prediabetes and diabetes before implementing evidence-based prevention and treatment interventions. We examined screening practices benchmarking against two US guidelines, and the capacity of each guideline to identify dysglycemia.

Methods: Using 2007-2012 National Health and Nutrition Examination Surveys, we analyzed nationally-representative, cross-sectional data from 5,813 fasting non-pregnant adults aged ≥20 years without self-reported diabetes. We examined proportions of adults eligible for diagnostic glucose testing and those who self-reported receiving testing in the past three years, as recommended by the American Diabetes Association (ADA) and the US Preventive Services Task Force (USPSTF-2008) guidelines. For each screening guideline, we also assessed sensitivity, specificity, and positive (PPV) and negative predictive values in identifying dysglycemia (defined as fasting plasma glucose ≥100 mg/dl or hemoglobin A1c ≥5.7%).

Results: In 2007-2012, 73.0% and 23.7% of US adults without diagnosed diabetes met ADA and USPSTF-2008 criteria for screening, respectively; and 91.5% had at least one major risk factor for diabetes. Of those ADA- or USPSTF-eligible adults, about 51% reported being tested within the past three years. Eligible individuals not tested were more likely to be lower educated, poorer, uninsured, or have no usual place of care compared to tested eligible adults. Among adults with ≥1 major risk factor, 45.7% reported being tested, and dysglycemia yields (i.e., PPV) ranged from 45.8% (high-risk ethnicity) to 72.6% (self-reported prediabetes). ADA criteria and having any risk factor were more sensitive than the USPSTF-2008 guideline (88.8-97.7% vs. 31.0%) but less specific (13.5-39.7% vs. 82.1%) in recommending glucose testing, resulting in lower PPVs (47.7-54.4% vs. 58.4%).

Conclusion: Diverging recommendations and variable performance of different guidelines may be impeding national diabetes prevention and treatment efforts. Efforts to align screening recommendations may result in earlier identification of adults at high risk for prediabetes and diabetes.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Percentage of US adults reporting…
Fig 1. Percentage of US adults reporting receipt of glucose testing by eligibility status according to diabetes screening guidelines.
Abbreviations: USPSTF, United States Preventive Services Task Force; ADA, American Diabetes Association. Data were from 5,813 adults without diagnosed diabetes in the 2007–2012 National Health and Nutrition Examination Survey. Receipt of glucose testing was defined as an affirmative answer to the question, “Have you had a blood test for high blood sugar or diabetes within the past three years?” Any risk factor is defined as: age ≥45 years, body mass index ≥ 25 kg/m2, family history of diabetes, high-risk ethnicity, history of gestational diabetes or prediabetes, or blood pressure ≥140/90 mmHg.

References

    1. Centers for Disease Control and Prevention National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta: US Department of Health and Human Services; 2014.
    1. Yang W, Dall TM, Halder P, Gallo P, Kowal SL, Hogan PF. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013; 36(4): 1033–46. 10.2337/dc12-2625
    1. Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007; 78(3): 305–12.
    1. Li Y, Geiss LS, Burrows NR, Rolka DB, Albright A. Awareness of Prediabetes—United States, 2005–2010. MMWR. 2013; 62(11): 209–12.
    1. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374(9702): 1677–86. 10.1016/S0140-6736(09)61457-4
    1. Lindström J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi S, et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013; 56(2): 284–93. 10.1007/s00125-012-2752-5
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577–89. 10.1056/NEJMoa0806470
    1. Cheng YJ, Imperatore G, Geiss LS, Wang J, Saydah SH, Cowie CC, et al. Secular Changes in the Age-Specific Prevalence of Diabetes Among U.S. Adults: 1988–2010. Diabetes Care. 2013; 36(9): 2690–6. 10.2337/dc12-2074
    1. Bullard KM, Saydah SH, Imperatore G, Cowie CC, Gregg EW, Geiss LS, et al. Secular Changes in U.S. Prediabetes Prevalence Defined by Hemoglobin A1c and Fasting Plasma Glucose: National Health and Nutrition Examination Surveys, 1999–2010. Diabetes Care. 2013; 36(8): 2286–93. 10.2337/dc12-2563
    1. Echouffo-Tcheugui JB, Ali MK, Griffin SJ, Narayan KM. Screening for type 2 diabetes and dysglycemia. Epidemiologic Reviews. 2011; 33(1): 63–87.
    1. Engelgau MM, Gregg EW. Tackling the global diabetes burden: will screening help? Lancet. 2012; 380(9855): 1716–8. 10.1016/S0140-6736(12)61682-1
    1. Wilson JGM, Jungner G. Principles and practice of screening for disease Geneva: World Health Organization; 1968.
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977–86.
    1. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008; 336(7654): 1180–5. 10.1136/bmj.39545.585289.25
    1. Chung S, Azar KM, Baek M, Lauderdale DS, Palaniappan LP. Reconsidering the age thresholds for type II diabetes screening in the U.S. Am J Prev Med. 2014; 47(4): 375–81. 10.1016/j.amepre.2014.05.012
    1. Calonge N, Petitti DB, DeWitt TG, Dietrich AJ, Gordis L, Gregory KD, et al. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine. 2008; 148(11): 846–54.
    1. American Diabetes Association. Standards of medical care in diabetes—2006. Diabetes Care. 2006; 29 Suppl 1: S4–42.
    1. National Institute for Health and Care Excellence. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk NICE guidelines; 2013; PH38. Available: .
    1. U.S. Preventive Services Task Force [Internet]. Rockville: USPSTF Program Office; [updated 2014 Oct; cited 2015 Mar 28]. Topic Update in Progress, Abnormal Glucose and Type 2 Diabetes Mellitus in Adults: Screening; [about 2 screens]. Available from: .
    1. Centers for Disease Control and Prevention [Internet]. Hyattsville: National Center for Health Statistics (NCHS); [updated 2105 Mar 20; cited 2015 Mar 28]. National Health and Nutrition Examination Survey: Questionnaires, Datasets, and Related Documentation [survey operations manuals, consent documents, brochures, and interview and exam manuals online]. Available from: .
    1. Centers for Disease Control and Prevention [Internet]. Hyattsville: National Center for Health Statistics (NCHS); [updated 2015 Feb 26; cited 2015 Mar 28]. National Health and Nutrition Examination Survey: laboratory protocol. Available from: .
    1. Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988–1994 and 1999–2010. Ann Intern Med. 2014; 160(8): 517–25. 10.7326/M13-2411
    1. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a WHO/IDF consultation Geneva: WHO Press; 2006. Available: .
    1. Sheehy AM, Flood GE, Tuan WJ, Liou JI, Coursin DB, Smith MA. Analysis of guidelines for screening diabetes mellitus in an ambulatory population. Mayo Clinic Proceedings. 2010; 85(1): 27–35. 10.4065/mcp.2009.0289
    1. Ratner RE. Diabetes management in the age of national health reform. Diabetes Care. 2011; 34(4): 1054–7. 10.2337/dc10-1987
    1. Casagrande SS, Cowie CC, Fradkin JE. Utility of the U.S. Preventive Services Task Force Criteria for Diabetes Screening. AJPM. 2013; 45(2): 167–74.
    1. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012; 379(9833): 2243–51. 10.1016/S0140-6736(12)60525-X
    1. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care. 1992; 15(7): 815–9.
    1. Plantinga LC, Crews DC, Coresh J, Miller ER 3rd, Saran R, Yee J, et al. Prevalence of Chronic Kidney Disease in US Adults with Undiagnosed Diabetes or Prediabetes. Clin J Am Soc Nephrol. 2010; 5(4): 673–82. 10.2215/CJN.07891109
    1. Park P, Simmons RK, Prevost AT, Griffin SJ. Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice. BMC Public Health. 2008; 8: 350 10.1186/1471-2458-8-350
    1. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2007; 335(7618): 486
    1. Glümer C1, Yuyun M, Griffin S, Farewell D, Spiegelhalter D, Kinmonth AL, et al. What determines the cost-effectiveness of diabetes screening? Diabetologia. 2006; 49(7): 1536–44.
    1. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007; 11(17): iii–iv, ix–xi, 1–125
    1. Diabetes Prevention Program Research Group. The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention: An intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012; 35(4): 723–30. 10.2337/dc11-1468
    1. Albright AL, Gregg EW. Preventing Type 2 Diabetes in Communities Across the U.S.: The National Diabetes Prevention Program. AJPM. 2013; 44(4): S346–S51. 10.1016/j.amepre.2012.12.009
    1. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med. 2013; 368(17): 1613–24. 10.1056/NEJMsa1213829

Source: PubMed

3
Tilaa